• Q2 to keep ~20% organic growth driven by both divisions • Margins continue to increase, 42% '23e-'...
-9% organisk tillväxt… Med 5-6% negativ påverkan från pris (fallande fraktpriser), vilket kommer for...
Q-linea continues to improve the network of European distribution partners and AST'ar is now represe...
Bolaget levererar på uppföljningsmålet och Fas 2b-studien med STA363 löper enligt plan.
Redeye sees strong preliminary results for ADDvise’s Q2.
Redeye comments on the topline result of the phase I trial of Lipisense, which demonstrated a favour...
Following its strategic plan, STRAX now has secured an investment of EUR10m from ZEBRA Invest GmbH, ...
Redeye is encouraged to see yet another quarter in which BONESUPPORT positively surprises us.
Redeye lowers its fair value range following the updated FDA timeline, which will likely hold the sh...
• We cut '23e-'25e adj. EBITA by 12-6% • Negative price/mix from inflation data continues • Trading ...
• Cost initiatives announced • One step closer to positive FCF • Trading at '23e EV/EBITDA of ~21x W...
Inför Q2-rapporten räknar Analysguiden med en lönsamhet under press men något ökad omsättning.
Redeye konstaterar att BioArctics rapport för det andra kvartalet kom in i linje med för förväntan, ...
• Adj. EBITA SEK 210m (-9% vs. ABGSCe 231m) • Cons.
Redeye comments on Coala Life's directed issue of cSEK17m.
• Q2 report due on Thursday, 20 July • Sequential earnings growth to continue, but down y-o-y • H2 c...
Migrationen av de nya kunderna slutförd Migrationen av Lunars P2P-kunder har gått bra och redan i mi...
Redeye comments on the latest information regarding Karpatens lawsuit.
Redeye provides its commentary on Coala Life based on the recently released Key Performance Indicato...
